Soma (Carisoprodol) 500mg
Soma (Carisoprodol) 500mg is a maximum strength oral prescription muscle-relaxant tablet intended for clinician-directed, short-term relief of discomfort associated with acute, painful musculoskeletal conditions in adults. It provides targeted acute muscle therapy and should be used with rest, physical therapy, and other medical measures.
Price: From $150.00
Category: Pain Relief
Brand: Soma
SKU: SOM500-1262
Availability: In Stock
Active Ingredient: Carisoprodol 500mg
Dosage Form: Tablets
Indication & Clinical Uses
Short-term relief of discomfort associated with acute, painful musculoskeletal conditions in adults Acute muscle strain accompanied by painful muscle spasm Acute sprain-related muscular discomfort following professional assessment Acute mechanical lower-back discomfort following professional assessment Short-term adjunct to rest and physical therapy Temporary activity-modification and rehabilitation plans Prescription skeletal muscle-relaxant treatment Short-duration treatment plans that ordinarily do not exceed two or three weeks
Dosage & Administration Guidance
Use Carisoprodol 500mg only according to the patient-specific prescription and the instructions supplied by the dispensing pharmacy. Confirm that the prescription, dispensing label and supplied package all identify the same 500mg strength. The 500mg strength is not an FDA-labeled U.S. Soma tablet strength. Current U.S. Soma labeling identifies 250mg and 350mg tablets and should not be used to independently calculate a dosage schedule for a 500mg product. Do not substitute a 500mg tablet for a 250mg or 350mg tablet. Do not take more than the prescribed quantity. Do not take the medicine more frequently than prescribed. Do not take additional tablets after a missed dose unless specifically directed by the prescriber or pharmacist. Carisoprodol treatment should ordinarily be limited to short periods of up to two or three weeks. Do not extend treatment without further professional assessment. Follow the supplied manufacturer instructions regarding use with or without food. Avoid alcohol. Do not combine Carisoprodol with opioids, benzodiazepines, sleeping medicines, sedating antihistamines, tricyclic antidepressants or other central nervous system depressants unless the combination has been professionally reviewed. Do not drive or operate machinery when drowsiness, dizziness, reduced coordination or slowed reactions occur. Do not abruptly discontinue the medicine after prolonged or excessive use without contacting the prescriber. Use additional caution in kidney impairment, liver impairment or reduced CYP2C19 activity. Safety, effectiveness and pharmacokinetics have not been established in patients younger than 16 years. Safety, effectiveness and pharmacokinetics have not been adequately established in adults older than 65 years. Inform the prescriber about pregnancy, planned pregnancy or breastfeeding before use.
Storage & Handling
Store Carisoprodol 500mg in its original, tightly closed and correctly labeled container. Recommended Storage Temperature: 20°C to 25°C / 68°F to 77°F, unless different conditions are stated on the supplied manufacturer packaging. Protect the tablets from excessive heat and moisture. Keep the medicine securely stored. Keep it out of the reach of children, pets and visitors. Store it where it cannot be accessed by anyone for whom it was not prescribed. Do not use tablets after the printed expiration date. Do not use tablets that appear damaged, discolored, contaminated or incorrectly labeled. Do not transfer the tablets into an unmarked container. Dispose of unused controlled medicine according to the instructions provided by the pharmacist or an authorized medicine take-back programme.
How to Use & Dosage Guidance
- Confirm the Prescription: Use Carisoprodol 500mg only when it has been prescribed specifically for the patient by a qualified healthcare professional.
- Verify the Product Strength: Confirm that the prescription, dispensing label and supplied package all state Carisoprodol 500mg. Do not substitute one tablet strength for another without professional approval.
- Review Current Medicines: Tell the prescriber and pharmacist about every prescription medicine, non-prescription product, herbal supplement and sedating substance currently being used.
- Follow the Patient-Specific Directions: Take the medicine only in the amount, frequency and treatment schedule written on the prescription and dispensing label.
- Limit the Treatment Period: Carisoprodol is intended for short-term treatment. Do not extend the treatment period without further professional assessment.
- Take as Directed: Swallow the tablet with water. Follow the supplied product instructions regarding administration with or without food.
- Avoid Alcohol and Sedatives: Do not consume alcohol. Check with the prescriber before using opioids, benzodiazepines, sleep medicines, sedating antihistamines or other central nervous system depressants.
- Avoid Driving When Affected: Do not drive, operate machinery or perform hazardous work when drowsiness, dizziness, slowed reactions or reduced coordination occur.
- Do Not Change the Dose: Do not take additional tablets, increase the frequency, share the medicine or replace the prescribed tablet strength without professional approval.
- Store Securely and Monitor Symptoms: Keep the medicine in its original labeled container and store it securely. Seek urgent medical care for severe sleepiness, breathing difficulty, fainting, seizure, severe confusion, hallucinations, loss of coordination or a serious allergic reaction.
Safety Warnings & Precautions
- Use only according to the prescription and supplied dispensing label.
- The 500mg strength is not an FDA-labeled U.S. Soma tablet strength.
- Do not calculate the 500mg dosing schedule from directions written for 250mg or 350mg tablets.
- Confirm the manufacturer, strength and product label before use.
- Treatment should ordinarily be limited to two or three weeks.
- Do not use for routine long-term chronic-pain management.
- Do not take more than the prescribed dose.
- Do not take the medicine more frequently than prescribed.
- Do not combine different Carisoprodol tablet strengths without professional approval.
- Carisoprodol may cause substantial drowsiness or sedation.
- Carisoprodol may cause dizziness and impaired coordination.
- Do not drive when affected.
- Do not operate machinery when affected.
- Avoid alcohol.
- Alcohol may increase sedation and breathing-related risks.
- Opioids may cause additive central nervous system and respiratory depression.
- Benzodiazepines may cause additive sedation and psychomotor impairment.
- Sleeping medicines may cause additive central nervous system depression.
- Sedating antihistamines may increase drowsiness and impairment.
- Tricyclic antidepressants may increase sedation.
- Other skeletal muscle relaxants may increase impairment.
- Do not combine Carisoprodol with Meprobamate unless specifically reviewed.
- Prolonged use may cause tolerance.
- Prolonged use may cause physical dependence.
- Abrupt discontinuation after prolonged use may cause withdrawal.
- Withdrawal may include insomnia, vomiting, abdominal cramps, headache, tremor or anxiety.
- Severe withdrawal may include impaired coordination, hallucinations or psychosis.
- Carisoprodol has recognized misuse, abuse and diversion risks.
- Keep the medicine securely stored.
- Do not share the medicine with another person.
- Seizures have been reported.
- Multiple-drug overdose substantially increases risk.
- Overdose may cause severe central nervous system depression.
- Overdose may cause respiratory depression.
- Overdose may cause low blood pressure.
- Overdose may cause delirium, hallucinations, coma or death.
- Use caution with CYP2C19 inhibitors.
- Omeprazole may increase Carisoprodol exposure.
- Fluvoxamine may increase Carisoprodol exposure.
- Use caution with CYP2C19 inducers.
- Rifampin may alter Carisoprodol and Meprobamate exposure.
- St. John’s wort may alter Carisoprodol and Meprobamate exposure.
- Use caution in kidney impairment.
- Use caution in liver impairment.
- Patients with reduced CYP2C19 activity may have increased Carisoprodol exposure.
- Safety is not established in patients younger than 16 years.
- Safety and pharmacokinetics are not adequately established in adults older than 65 years.
- Inform the prescriber about pregnancy or breastfeeding.
- Monitor a breastfed infant for unusual sedation when maternal treatment is professionally considered necessary.
- Keep the medicine away from children and pets.
- Do not use damaged, contaminated or expired tablets.
- Seek urgent medical care for breathing difficulty, severe sedation, seizure, fainting, hallucinations, loss of coordination or unresponsiveness.
Contraindications
- Acute intermittent porphyria
- Known hypersensitivity to Carisoprodol
- Known hypersensitivity to Meprobamate
- Known hypersensitivity to another carbamate medicine
- Known serious hypersensitivity to any ingredient contained in the supplied tablet formulation
- The official labeled contraindications include acute intermittent porphyria and hypersensitivity to a carbamate such as Meprobamate.
Drug Interactions
- Alcohol — additive sedation, impaired coordination and central nervous system depression
- Opioids — additive central nervous system and respiratory depression
- Benzodiazepines — additive sedation and psychomotor impairment
- Barbiturates — additive central nervous system depression
- Tricyclic antidepressants — additive sedation
- Sedating antihistamines — increased drowsiness and impairment
- Sleeping medicines — additive central nervous system depression
- Sedating antipsychotic medicines — increased sedation and impairment
- Other skeletal muscle relaxants — additive sedation and reduced coordination
- Meprobamate — active-metabolite duplication and increased sedation; concomitant use is not recommended
- Omeprazole — may increase Carisoprodol exposure through CYP2C19 inhibition
- Fluvoxamine — may increase Carisoprodol exposure through CYP2C19 inhibition
- Other CYP2C19 inhibitors — may increase Carisoprodol exposure and reduce Meprobamate exposure
- Rifampin — may decrease Carisoprodol exposure and increase Meprobamate exposure
- St. John’s wort — may decrease Carisoprodol exposure and increase Meprobamate exposure
- Other CYP2C19 inducers — may alter Carisoprodol and Meprobamate exposure
- Cannabis and other sedating substances — may increase drowsiness and psychomotor impairment
- Medicines that lower blood pressure — may worsen dizziness, fainting or postural symptoms
- Multiple sedating medicines — increased overdose, respiratory-depression and impairment risk
Potential Side Effects
- Drowsiness
- Sedation
- Dizziness
- Headache
- Vertigo
- Impaired coordination
- Ataxia
- Tremor
- Agitation
- Irritability
- Depressive reactions
- Fainting
- Insomnia
- Nausea
- Vomiting
- Upper-abdominal discomfort
- Increased heart rate
- Postural low blood pressure
- Facial flushing
- Muscle twitching
- Confusion
- Hallucinations
- Psychosis
- Seizure
- Serious allergic reaction
- Breathing difficulty
- Central nervous system depression
- Respiratory depression in overdose
- Low blood pressure in overdose
- Delirium in overdose
- Blurred vision in overdose
- Coma in overdose
- Drowsiness, dizziness and headache are the most frequently reported adverse reactions in controlled studies involving FDA-labeled Soma strengths.
Frequently Asked Questions
- What is Soma (Carisoprodol) 500mg?
- It is an oral prescription product containing Carisoprodol 500mg, a centrally acting skeletal muscle relaxant.
- What is Carisoprodol used for?
- Carisoprodol is indicated for the short-term relief of discomfort associated with acute, painful musculoskeletal conditions in adults.
- Is Carisoprodol intended for long-term chronic pain?
- No. Carisoprodol treatment is generally limited to short periods of up to two or three weeks.
- Is Carisoprodol an opioid?
- No. Carisoprodol is a centrally acting skeletal muscle relaxant, not an opioid.
- Is 500mg an official U.S. Soma strength?
- No. Current U.S. Soma prescribing information lists 250mg and 350mg tablets. The supplied 500mg product must be identified according to its actual manufacturer label and applicable jurisdiction.
- How should the 500mg tablet be taken?
- Follow the exact dose, frequency and treatment duration written on the prescription and dispensing label. Do not infer a dose from information written for another tablet strength.
- Can the tablet be divided?
- Do not divide, crush or alter the tablet unless the manufacturer label, prescriber or pharmacist specifically confirms that it is appropriate.
- Can Carisoprodol cause drowsiness?
- Yes. Drowsiness and sedation may impair driving, machinery operation and other activities requiring alertness.
- Can Carisoprodol cause dizziness?
- Yes. Dizziness, vertigo and impaired coordination have been reported.
- Can alcohol be consumed with Carisoprodol?
- Alcohol may increase sedation, dizziness, impaired coordination and breathing-related risks and should be avoided.
- Can Carisoprodol be combined with opioids?
- The combination may cause additive central nervous system and respiratory depression and requires specific professional review.
- Can Carisoprodol be combined with benzodiazepines?
- The combination may substantially increase sedation, slowed reactions and psychomotor impairment.
- Can Carisoprodol cause dependence?
- Yes. Misuse, tolerance, physical dependence and withdrawal have been reported, particularly with prolonged or excessive use.
- What withdrawal symptoms may occur?
- Reported symptoms include insomnia, vomiting, abdominal cramps, headache, tremor, anxiety, muscle twitching, impaired coordination, hallucinations and psychosis.
- Can Carisoprodol cause seizures?
- Seizures have been reported, particularly in multiple-drug overdose situations involving alcohol, sedatives or other substances.
- Who must not use Carisoprodol?
- It is contraindicated in patients with acute intermittent porphyria or a hypersensitivity reaction to Carisoprodol, Meprobamate or another carbamate medicine.
- Can patients younger than 16 use Carisoprodol?
- Safety, effectiveness and pharmacokinetics have not been established in patients younger than 16 years.
- Can adults older than 65 use Carisoprodol?
- Safety, effectiveness and pharmacokinetics have not been adequately established in adults older than 65 years. Individual professional assessment is required.
- How should Carisoprodol be stored?
- Store the medicine in a tightly closed container at controlled room temperature, generally between 20°C and 25°C or 68°F and 77°F, unless the supplied manufacturer label states otherwise.
- Which symptoms require urgent medical attention?
- Seek urgent medical attention for severe drowsiness, slow or difficult breathing, fainting, seizure, severe confusion, hallucinations, loss of coordination, coma, unresponsiveness or a serious allergic reaction.
Medically reviewed by CureHealth Clinical Review Board. Compliant with standard US pharmacy reference guidelines.